Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Time to share: lessons from post hoc analyses of IPF trials.

Literature DB >> 27789650

Time to share: lessons from post hoc analyses of IPF trials.

Daniel J Kass¹, Naftali Kaminski².

Abstract

Entities: Chemical Disease Gene Species

Keywords: Idiopathic pulmonary fibrosis

Mesh：

Year: 2016 PMID： 27789650 PMCID： PMC5994758 DOI： 10.1136/thoraxjnl-2016-209293

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139

Keyword Cloud
References

× No keyword cloud information.

21 in total

1. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Talmadge E King; Lisa Lancaster; Paul W Noble; Steven A Sahn; Michiel Thomeer; Dominique Valeyre; Athol U Wells
Journal: Am J Respir Crit Care Med Date: 2011-09-22 Impact factor: 21.405

Review 2. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.

Authors: Antonio B Fernández; Richard H Karas; Alawi A Alsheikh-Ali; Paul D Thompson
Journal: Chest Date: 2008-08-08 Impact factor: 9.410

3. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors: Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405

4. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.

Authors: Michael Kreuter; Wim Wuyts; Elisabetta Renzoni; Dirk Koschel; Toby M Maher; Martin Kolb; Derek Weycker; Paolo Spagnolo; Klaus-Uwe Kirchgaessler; Felix J F Herth; Ulrich Costabel
Journal: Lancet Respir Med Date: 2016-03-31 Impact factor: 30.700

Time to share: lessons from post hoc analyses of IPF trials.

1. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

Review 2. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.

3. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

4. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.

5. Statins and the risk of interstitial lung disease: a cohort study.

6. Subgroup analysis and other (mis)uses of baseline data in clinical trials.

7. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.

8. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis.

9. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.

10. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.